Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
INAB | US
0.00
0.52%
Healthcare
Biotechnology
30/06/2024
17/10/2024
0.23
0.23
0.23
0.22
IN8bio Inc. a clinical-stage biopharmaceutical company focuses on the discovery development and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200 a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100 an allogeneic product candidate which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400 which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300 INB-410 and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics Inc. and changed its name to IN8bio Inc. in August 2020. IN8bio Inc. was incorporated in 2016 and is headquartered in New York New York.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
65.8%1 month
65.4%3 months
92.8%6 months
106.7%-
-
1.20
0.43
0.26
-1.15
-
-
-30.63M
16.69M
16.69M
-
-
-
-
-180.45
0.44
0.61
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.06
Range1M
0.13
Range3M
0.67
Rel. volume
0.82
Price X volume
67.68K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Minerva Neurosciences Inc | NERV | Biotechnology | 2.58 | 18.04M | -3.37% | n/a | -194.60% |
Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 0.4456 | 17.88M | -0.49% | n/a | 2.71% |
Inhibikase Therapeutics Inc. | IKT | Biotechnology | 2.35 | 17.54M | 21.13% | n/a | 3.49% |
Kazia Therapeutics Limited | KZIA | Biotechnology | 0.5269 | 17.54M | 58.04% | n/a | 6.82% |
Athira Pharma Inc | ATHA | Biotechnology | 0.4477 | 17.21M | -1.52% | n/a | 1.69% |
GeoVax Labs Inc | GOVX | Biotechnology | 2.01 | 17.15M | -4.29% | n/a | -6.03% |
ICU | ICU | Biotechnology | 4.02 | 16.85M | -4.29% | n/a | -45.50% |
Synlogic Inc | SYBX | Biotechnology | 1.42 | 16.61M | -1.39% | n/a | 0.00% |
Can-Fite BioPharma Ltd | CANF | Biotechnology | 2.7 | 16.46M | 0.00% | n/a | 0.64% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.71 | 15.99M | 0.00% | n/a | 837.11% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.15 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 1.20 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 92.76 | 72.92 | Riskier |
Debt to Equity | 0.43 | -1.24 | Expensive |
Debt to Assets | 0.26 | 0.25 | Par |
Market Cap | 16.69M | 3.78B | Emerging |